Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced on Thursday an expansion of Cronos Growing Company, a cannabis cultivation business that the Toronto-based company owns 50% of.The investment will be funded by a roughly $51 million (CA$70 million) secured non-revolving credit facility provided by Cronos. It will assist GrowCo's expansion of its purpose-built cannabis facility in Leamington, Ontario, that will produce high-quality cannabis flower, the company said in a press release., Under the four-year supply deal between Cronos and GrowCo and prior to the first sale of products from the newly constructed area, Cronos will have the option to buy roughly 80% of GrowCo's production. Once first sales from the newly constructed area occur, Cronos will have the option to purchase 70% of all GrowCo's supplies on an annual basis.
Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met all primary and secondary endpoints.
Crypto venture capitalist Andrew Kang sees the delayed Ethereum (CRYPTO: ETH) ETF causing market momentum to shift from upward to downward, particularly due to the lack of acute ETF inflows.
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod.
The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments.